anti-OX40L (human), mAb (rec.) (blocking) (R4930) (preservative free)

Specifications / Handling

More Information
Product Details
Synonyms	CD252; CD134L; OX40 Ligand; TNFSF4; Tumor Necrosis Factor Superfamily Member 4; TAX Transcriptionally-activated Glycoprotein 1; TXGP1; gp34
Product Type	Recombinant Antibody
Properties
Clone	R4930
Isotype	Human IgG1κ
Source/Host	CHO cells
Immunogen/Antigen	Recombinant human OX40L.
Label/Conjugates	Preservative Free
Application	Flow Cytometry: 1µg/ml Functional Application (Blocking): Binds to the co-stimulatory human OX40L inhibiting its interaction with OX40 in vitro and in vivo. Optimal conditions should be determined individually for each application.
Crossreactivity	Human
Specificity	Recognizes human OX40L.
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein A-affinity purified.
Endotoxin Content	<0.001EU/μg
Concentration	1mg/ml
Formulation	Liquid. In PBS.
Isotype Negative Control	Human IgG1 Isotype Control (preservative free)
Other Product Data	This antibody is a biosimilar generically called Oxelumab (CAS 1186098-83-8) and originally developed by Genentech. Oxelumab is a OX40 ligand blocker designed for the prevention of allergen-induced airway inflammation in adults with mild asthma. Potentially other application areas are transplantation and autoimmunity research or protection against inflammation-driven fibrosis.
Accession Number	UniProt ID P23510
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

OX40L [CD252; CD134L] is a membrane-expressed cytokine that belongs to the TNF ligand family. It acts as costimulator through interaction with its ligand OX40 on T cells, stimulating T cell activation, proliferation and cytokine production. OX40L is expressed on antigen presenting cells including B cells, dendritic cells, mast cells and endothelium.

Product References

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation: D. Seshasayee, et al.; J. Clin. Invest. 117, 3868 (2007)
Monoclonal antibodies for the treatment of asthma: M.C. Catley, et al.; Pharm. Ther. 132, 333 (2011)
OX40L blockade and allergen-induced airway responses in subjects with mild asthma: G.M. Gauvreau, et al.; Clin. Exp. Allergy 44, 29 (2014)

Call	+41 61 926 6040
Fax	+41 61 926 6049